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To evaluate run-off computed tomography angiography (CTA) of abdominal aorta and lower
extremities for detecting musculoskeletal pathologies and clinically relevant extravascular
incidental findings in patients with intermittent claudication (IC) and suspected peripheral
arterial disease (PAD). Does run-off CTA allow image-based therapeutic decision making
by discriminating the causes of intermittent claudication in patients with suspected periph-
eral arterial disease PAD?
Material and Methods
Retrospective re-evaluation of CTAs performed in patients with acute or chronic intermittent
claudication (i.e., Fontaine stages I to IIB) between January 2005 and October 2013. Alloca-
tion to one of three categories of underlying causes of IC symptoms: vascular, musculoskel-
etal (MSK) or both. Clinically relevant extravascular incidental findings were evaluated.
Medical records were reviewed to verify specific therapies as well as main and incidental
findings.
Results
While focused on vascular imaging, CTA image quality was sufficient for evaluation of the
MSK system in all cases. The underlying cause of IC was diagnosed in run-off CTA as
vascular, MSK and a combination in n = 138 (65%), n = 10 (4%), and n = 66 (31%) cases,
respectively. Specific vascular or MSK therapy was recorded in n = 123 and n = 9 cases. In
n = 82, no follow-up was possible. Clinically relevant extravascular incidental findings were
detected in n = 65 patients (30%) with neoplasia, ascites and pleural effusion being the
most common findings.
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Discussion
Run-off CTA allows identification of vascular, MSK, and combined causes of IC in patients
with suspected PAD and can guide specific therapy. CTA also allowed confident detection
of crEVIF although detection did not necessarily trigger workup or treatment.
Introduction
Intermittent claudication (IC) is a typical symptom of peripheral arterial disease (PAD). In
some cases, the patient’s history and clinical examination alone allow differentiation of PAD
from other underlying conditions such as lumbar spinal stenosis: vascular claudication typi-
cally occurs after walking and is associated with a decreased ankle-brachial index (ABI) [1],
whereas neurogenic claudication, e.g., caused by lumbar spinal stenosis, is typically associated
with activity and spinal position [2]. However, due to differences in subjective perception of
symptoms, the exact diagnosis often cannot be made on clinical examination alone and ulti-
mately requires imaging [2–4].
Run-off computed tomography angiography (CTA) has become the method of choice for
non-invasive imaging of the aorta and lower limb vessels in patients with suspected PAD [5]
and is considered to be more accurate than arterial duplex sonography [6]. While still consid-
ered the diagnostic standard of reference for PAD, digital subtraction angiography (DSA) is
currently being replaced by non-invasive imaging techniques such as CTA or magnetic reso-
nance angiography (MRA) [7,8]. Several studies have shown that CTA is highly accurate in
detecting arterial stenosis while avoiding common complications associated with invasive DSA
[9]. Furthermore, CTA has become widely used because it is fast and well tolerated by patients
and allows precise treatment planning even when using low-dose protocols [10,11].
Although the focus is on the vascular system, CTA allows assessment not only of the vascu-
lar situation of the aorta and lower extremities but also of the appearance of extravascular
structures such as the musculoskeletal system [12,13]. To the best of our knowledge, a study
investigating the incidence of nonvascular underlying causes and combined vascular and mus-
culoskeletal pathologies in patients with intermittent claudication has not been done before.
The aim of the present study therefore was to evaluate run-off CTA of the abdominal aorta
and lower extremities for identification of nonvascular underlying causes of IC and detection
of clinically relevant extravascular incidental findings (crEVIF) in patients with intermittent
claudication and suspected PAD. The study also aimed at determining to what extent run-off
CTA could serve as an imaging method for guiding therapy by discriminating the origin of
intermittent claudication in patients with suspected PAD.
Material and Methods
Patients
This retrospective study was approved by the institutional review board (IRB; EA4/058/13) of
Charité-Universitätsmedizin Berlin. Written informed consent was given from all patients for
using imaging data and medical records for study purposes and imaging data were not anon-
ymized prior to analysis. The radiological database was screened for patients who underwent
CTA because of acute or chronic intermittent claudication (i.e., symptoms corresponding to
stages I to IIB according to Fontaine classification) between January 2005 and October 2013.
Patients with symptoms indicating stage III or IV disease were excluded from our retrospective
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analysis since those stages are associated with stable rather than intermittent symptoms or
always have a vascular pathology as the underlying cause. Categorization was based on clinical
information.
Imaging
Run-off CTA had a scan range extending from the costodiaphragmatic recess to the forefoot
and was conducted either on a 64-slice CT scanner (Somatom Definition1, Siemens Health-
care, Erlangen, Germany) or on a 16-slice CT scanner (Somatom Sensation 161, Siemens
Healthcare, Erlangen, Germany). 64-slice CT was acquired with the following parameters: tube
voltage 120 kVp, reference tube current-time product 120 mAs with tube current modulation
CareDose4D1, rotation time 0.33 s; collimation 2 x 32 x 0.6 mm, pitch 0.75. CT scans on the
16-slice CT scanner were performed using the following acquisition parameters: tube voltage
120 kVp, reference tube current-time product 120 mAs with tube current modulation Care-
Dose4D1, rotation time 0.75 s; collimation 16 x 1.5 mm, pitch 1.5.
CTA was performed with the patient supine. A dose of 100 ml of iomeprol 400 mg I/ml
(Imeron 4001, Bracco, Milano, Italy), followed by a 60 ml saline flush, both at a flow rate of 4.0
ml/s, was injected using a dual-barrel injector (Stellant1, Medrad, Volkach, Germany) via a 20
G or larger IV cannula placed preferably in an antecubital vein. Arterial-phase images were
obtained 10 s after bolus detection in the suprarenal aorta (threshold 250 HU, CareBolus1, Sie-
mens Healthcare). For vascular assessment, images were first reconstructed using a soft kernel
(B25f) with a field of view of 330 mm and an effective slice thickness of 1.0 mm (reconstruction
interval 0.7 mm) for 64-slice CT and 2.0 mm (reconstruction interval 1.0 mm) for 16-slice CT.
Second, images were reconstructed with a larger field of view adjusted to the patient’s size and
using a slice thickness of 5.0 mm (64-slice CT) and 6.0 mm (16-slice CT) for display of the
whole patient. Additionally, in every patient coronal and sagittal reformations as well as MIP
reconstructions were done.
Image review
CTA datasets were evaluated by two trained readers focusing on findings explaining symptoms
of IC and clinically relevant extravascular incidental findings (crEVIF) requiring further diag-
nostic workup and/or immediate therapy according to the currently accepted state of the art
[14–16]. All images were reviewed using Visage 7 (Pro Medicus Ltd., Richmond, Australia).
Patients were allocated to one of three categories based on the imaging finding best explain-
ing symptoms of IC: 1 = vascular pathology (VASC), 2 = musculoskeletal (MSK) pathology or
3 = combined vascular and MSK pathology (COMB). Regarding MSK IC, we classified the fol-
lowing findings as possibly causing IC-like symptoms: absolute spinal stenosis (defined as a
combination of bilateral facet arthrosis, disk bulging or herniation and hypertrophy of the liga-
mentum flavum causing narrowing of the sagittal diameter of the spinal canal), intervertebral
disk herniation, vertebral body fracture, and severe joint diseases (coxarthrosis, gonarthrosis,
chondrocalcinosis) [17–20].
Morphologic criteria were used to define crEVIF [15,16,21]. The following findings were
considered as clinically relevant: lesions with imaging appearance suggesting malignancy or
indirect signs of malignancy (e.g., double duct sign), infectious diseases with or without accom-
panying findings (e.g. effusion), hernia, organomegaly, injuries and urinary obstruction.
Patients with crEVIF were assigned to subgroups of the aforementioned categories 1–3. To ver-
ify the major IC-related finding and incidental findings identified by CTA, we reviewed medi-
cal history forms and/or patient records. Following this review, patients were re-allocated to
one of three groups based on what kind of therapy was initiated based on IC-related findings at
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CTA: 1 = therapy focused on detected vascular pathology, 2 = therapy focused on detected
MSK pathology, 3 = no therapy noted in medical history. Treatment or follow-up of crEFIV
was evaluated separately. Statistical analysis was performed using SPSS 23 for Macintosh OS X
(IBM, Armonk, USA). Descriptive statistics of leading differential diagnosis for IC and inciden-
tal findings were performed. Means and standard deviations (SDs) of all acquired continuous
variables were calculated.
Results
Four hundred and twenty-nine patients with IC who had run-off CTA between January 2005
and October 2013 were identified. Of those, 214 patients had acute or chronic symptoms of
intermittent claudication corresponding to Fontaine stages I—IIb. Mean age was 70 years (SD
+/- 10.1 years). Sixty-five patients (29.4%) were women. All CTA datasets allowed assessment
of the vascular tree and of the lumbar spine, hip and knee. No patients had to be excluded from
retrospective analysis due to insufficient visualization of the spine, hip and knee.
An underlying vascular cause for symptoms of IC was detected by CTA in 138 cases (65%).
In 66 cases (31%), vascular and MSK findings were identified, an example is presented in Fig 1.
In the remaining 10 cases (4%), CTA demonstrated no vascular pathology but MSK findings
explaining the patients’ symptoms, as shown in Fig 2. Clinically relevant EVIFs were found in
65 cases (30% of all patients). Patients with predominantly vascular pathologies had the highest
percentage of crEVIF (47 of 138 cases; 22%), followed by patients with combined vascular and
MSK pathologies (17 of 66 cases; 8%) and MSK pathologies alone (1 of 10; 0.4%). The distribu-
tion of underlying causes of IC and of subgroups with additional crEVIF is presented in Fig 3.
One hundred and twenty-three patients with vascular pathologies detected by CTA subse-
quently underwent vascular therapy (e.g., percutaneous transluminal angioplasty (PTA), surgi-
cally implanted vascular prosthesis), whereas 9 patients with MSK-related pathologies
underwent orthopedic treatment (e.g., spinal fusion, spinal decompression). The data on treat-
ment following CTA are summarized in Table 1. In 82 of 214 cases (38%), no therapy was men-
tioned in the medical records. Sixty-nine (84%) of those patients with no recorded therapy
suffered from chronic IC-like symptoms rather than acute symptoms such as pain, paleness or
pulselessness. Follow-up data on therapy or further diagnostic workup of detected crEVIF were
available in 28 of 65 cases (43%). These data are summarized in Table 2.
Discussion
Our retrospective analysis shows that, in an older patient population with intermittent claudi-
cation and suspected PAD, nearly a third of the patients have a combination of vascular and
musculoskeletal findings explaining their symptoms. In 4% of the cases, musculoskeletal find-
ings alone were identified as the underlying cause of IC. With the standard imaging protocol
used for run-off CTA in this study not only assessment of the vascular tree but also identifica-
tion of possible musculoskeletal causes of IC is possible. Therefore, run-off CTA enables strati-
fication of IC patients for specific therapy.
To our knowledge, this is the first study to evaluate three categories, vascular, musculoskele-
tal and combined pathology, in patients with IC and the treatment initiatiated on the basis of
CTA findings. Previous studies focused on the comparison of imaging methods—CT and mag-
netic resonance imaging (MRI)—in PAD or the diagnostic quality for detecting lumbar spinal
stenosis in CT and MRI [18,22,23]. Musculoskeletal pathologies are the primary differential
diagnosis in patients with suspected PAD, and our results show that run-off CTA allows ade-
quate assessment of both pathologic conditions in one imaging procedure. In 31% of the cases,
concomitant vascular pathology and clinically relevant musculoskeletal findings warranted a
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change and/or extension of vascular therapy. In 4% of the cases the therapeutic regimen was
completely changed, as the suspected vascular pathology was not be confirmed by CTA. Since
this retrospective analysis included patient population already suspected of having PAD,
patients with lumbar spinal stenosis might be underrepresented and their percentage might be
higher in a nonpreselected population.
As known from previous studies, the morphologic imaging appearance of osteoarthritic and
intervertebral disk changes often does not correlate with disease severity or the patient’s clinical
symptoms [24,25]. Specialized imaging methods using axial loading during MRI allow better
identification of lumbar spinal stenosis but are not widely available[26]. The main limitation of
this retrospective study is that a detailed clinical examination in the group of combined vascu-
lar and MSK pathologies after run-off CTA is missing, so that the leading cause of IC could not
be fully elucidated. MSK findings might aggravate IC symptoms in part of the patients and
should be recognized as a possible target relevant for further therapies.
Fig 1. Example of a patient with known chronic PAD. The MIP (30° LAO) on the left shows the patient’s
complex vascular situation with iliacofemoral crossover bypass and chronic SFA occlusions. The right side
shows the lumbar spine with herniated vertebral disk between the fourth and fifth lumbar vertebrae and
consecutive lumbar spinal stenosis (arrow).
doi:10.1371/journal.pone.0152780.g001
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Our further analysis revealed that 123 of 214 patients had vascular therapy based on imag-
ing findings. In 9 cases specific musculoskeletal therapies were performed. Unfortunately, 82
cases (38%) were lost to follow-up, among them 69 patients with chronic IC. Only 13 patients
had acute symptoms. Possibly these patients with chronic IC and well-known symptoms
received conservative outpatient treatment with community doctors that was not recorded in
the hospital database.
In this retrospective study, the images were reread by two trained readers in consensus
focussing on MSK differential diagnosis and crEVIFs. In this way, possible underestimation of
musculoskeletal findings or crEVIFs due to underreporting can be ruled out [14]. Of note, the
results of the current study have changed our reporting regimen. Previously, a vascular radiolo-
gist alone read run-off CTAs. Now, double–reading with a general radiologist is the standard
procedure. It was beyond the scope of our study to determine the rates of MSK and crEVIF
findings identified in the the initial reading done by a vascular radiologist alone.
In addition to identification of the underlying causes of intermittent claudication, we
detected clinically relevant extravascular incidental findings (crEVIFs) in 30% of patients, i.e.
Fig 2. Example of a patient presenting with intermittent claudication. The maximum intensity projection
(MIP, 30° left anterior oblique, LAO) presented on the left side clearly excludes relevant vascular pathology
accounting for the clinical symptoms. On the right, a 4 mm average projection of the lumbar spinal canal
clearly depicts a compression fracture of the fourth lumbar vertebra with spinal stenosis (arrow).
doi:10.1371/journal.pone.0152780.g002
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65 cases. Newly diagnosed cancer was identified in 27 patients, which was confirmed on fol-
low-up in 12 cases. Previously unknown infections were found in 5 cases. Both findings are
highly important as cancer survival rates significantly decrease in patients with metastatic dis-
ease compared to local cancer [27]. In elderly patients, infectious diseases may remain clinically
silent and might have a poorer clinical outcome [28]. The rate of newly detected or suspected
Fig 3. Pie chart for distribution of origin of intermittent claudication assessed with run-off CTA. The
chart presents the distribution and incidence of vascular (VASC), musculoskeletal (MSK), and combined
(COMB) causes of intermittent claudication. Additionally, the percentage of patients with clinically relevant
extravascular incidental findings (crEVIFs) is displayed for each group (+crEVIFs, shaded area). In the vast
majority of cases IC is due to vascular pathology (96%). In 31% of the cases coexisting musculoskeletal
findings might also explain intermittent claudication. In only 4% of cases was MSK pathology identified as the
only underlying cause.
doi:10.1371/journal.pone.0152780.g003
Table 1. Distribution of therapies initiated after detection of either vascular or MSK pathologies by CTA.
Primary pathology detected in CTA Therapy Number of cases
Vascular (n = 123) Embolectomy/ Surgical intervention 36
PTA with stent placement 34





Musculoskeletal (n = 9) Spinal fusion 4
Periradicular therapy 4
Drug therapy 1
In both groups most patients had surgical or radiological interventions. Conservative therapy was only performed in a small fraction of patients. Numbers
are given as absolute values.
doi:10.1371/journal.pone.0152780.t001
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malignancies (27 / 214 = 12.6%) is above the published range of 2.5% to 3.5%, which might be
due to older age and the presence of known risk factors in patients with IC [15,29].
In 18 cases, previously unknown large pleural effusion or ascites led to immediate further
clinical workup to differentiate between cardiac, hepatic, infectious, and neoplastic origin. In
two cases, pleural effusion was caused by pneumonia. In 7 cases, optimization of specific car-
diac insufficiency therapy was recorded. Although we do not have data on this it can be
assumed that the radiological findings were reported to the transferring external physician and
community doctor and led to initiation of specific therapy. The follow-up rate of the crEVIF
was only slightly lower than described in the literature, i.e., 43%, compared to 58% or 61.7%
[15,29,30]. However, the follow–up data of the 65 crEVIFs detected on run-off CTA confirmed
that incidental detection led to specific treatment and presumably resulted in a more favorable
clinical course for the patients. The incidence of crEVIFs differs greatly with the anatomic
regions imaged, ranging between 6.7% in a cardiac CT study, 8.7% for the head and neck region
and up to 48.8% in thoracoabdominal CT angiography [14,15,30,31]. Therefore, the rate of
30% in our study seems plausible. Of note, the patients of our cohort were significantly older






Pleural effusion 9 Conﬁrmation of cardiac insufﬁciency as the underlying cause
leading to optimization of therapy (4)
Pneumonia (2)
No follow-up recorded (3)
Ascites 9 Reduction of ascites by drainage and/or drug therapy (3)
No follow-up recorded (6)
Adrenal mass 7 Conﬁrmed as primary or metastasis in follow-up CT (4)
No follow-up recorded (3)
Double duct sign 7 No follow-up recorded (7)
Pulmonary mass 6 Conﬁrmed as primary or metastasis in follow-up CT (4)
No follow-up recorded (2)
Hernia 6 Surgical intervention for treating an inguinal hernia (1)
No follow-up recorded (5)
Renal cyst (2F) 5 No follow-up recorded (5)
Urothelial carcinoma 3 Surgical intervention and/ or chemotherapy (3)
Pneumonia 2 Antibiosis (2)
Obstructive uropathy 2 No follow-up recorded (2)
Prostatitis 1 Intravenous antibiosis (1)
Renal cell carcinoma 1 Chemotherapy (1)
Ruptured spleen 1 Splenectomy (1)
Colitis 1 Conﬁrmed as ischemic colitis with embolectomy performed as
therapy of choice (1)
Sigmoid diverticulitis 1 Conservative treatment with intravenous antibiosis (1)
Hepatocellular
carcinoma
1 No follow-up recorded (1)
Splenomegaly 1 No follow-up recorded (1)
Pancreatic mass 1 No follow-up recorded (1)
Hepatic lesion 1 No follow-up recorded (1)
Pleural effusion, ascites and direct or indirect signs of malignancy were the most common crEVIFs in our
patient population. Medical records reported subsequent therapies or further examination in 28 cases.
doi:10.1371/journal.pone.0152780.t002
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and had concomitant vascular diseases (e.g., PAD or coronary artery disease) and other comor-
bidities such as renal impairment.
Conclusion
Although the focus is on vascular assessment, run-off CT angiography of the aorta and lower
extremities also allows differentiation of vascular and musculoskeletal causes of intermittent
claudication in a single examination. It facilitates therapeutic decision-making since a consid-
erable number of patients have clinically relevant musculoskeletal findings such as lumbar
spinal stenosis or combined vascular and musculoskeletal pathology. Clinically relevant extra-
vascular incidental findings are common on run-off CTA and can be identified on the basis of
their CT morphology.
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